Study Status: RECRUITING
Recruit Status: RECRUITING
Study Type: INTERVENTIONAL
Official Title: Obeticholic Acid for Prevention in Barrett's Esophagus
Brief Summary: This phase II trial studies the effect of obeticholic acid in treating patients with Barrett's esophagus.
Bile acids present in duodenogastroesophageal reflux contribute to neoplastic progression in Barrett's esophagus.
Obeticholic acid has shown anti-cholestatic, anti-inflammatory and anti-fibrotic effects mediated by FXR activation.
It down regulates bile acid availability and decreases proinflammatory cytokine production including IL-1? and TNF? in human enterocytes and immune cells.
This chain of events reduces the bile acid exposure in esophagus tissue thereby limiting bile acid induced damage and dysplastic progression.